{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Baird RD"],"funding":["NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC)","NIHR Cambridge Biomedical Research Centre","AstraZeneca (AstraZeneca PLC)","AstraZeneca","Cancer Research UK Cambridge Centre","Cambridge Experimental Cancer Medicine Centre"],"pagination":["4244-4254"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12521909"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(20)"],"pubmed_abstract":["<h4>Purpose</h4>This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor-positive, HER2- advanced breast cancer.<h4>Patients and methods</h4>SERENA-1 (NCT03616587) is a phase I, multipart, open-label study in women with refractory estrogen receptor-positive, HER2- advanced breast cancer. Patients received oral once-daily camizestrant 75 or 150 mg plus abemaciclib; camizestrant 75, 150, or 300 mg plus palbociclib; or camizestrant 75 mg plus ribociclib 400 or 600 mg. Safety/tolerability, pharmacokinetics, efficacy, and impact on estrogen receptor 1 mutation ctDNA were assessed.<h4>Results</h4>By September 16, 2024 (data cutoff), 53 patients had received camizestrant plus abemaciclib, 78 camizestr"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1."],"pmcid":["PMC12521909"],"funding_grant_id":["BRC-1215-20014"],"pubmed_authors":["Yang J","Ciardullo C","Morrow CJ","Incorvati J","Moreno I","Hamilton E","Mathewson AM","Sykes A","Bermejo de Las Heras B","Lindemann JPO","Victoria I","Armstrong A","Ruiz-Borrego M","Ciruelos E","Twelves C","Kabos P","Oliveira M","Patel MR","Klinowska T","Turner N","Baird RD","Vaklavas C","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.","description":"<h4>Purpose</h4>This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor-positive, HER2- advanced breast cancer.<h4>Patients and methods</h4>SERENA-1 (NCT03616587) is a phase I, multipart, open-label study in women with refractory estrogen receptor-positive, HER2- advanced breast cancer. Patients received oral once-daily camizestrant 75 or 150 mg plus abemaciclib; camizestrant 75, 150, or 300 mg plus palbociclib; or camizestrant 75 mg plus ribociclib 400 or 600 mg. Safety/tolerability, pharmacokinetics, efficacy, and impact on estrogen receptor 1 mutation ctDNA were assessed.<h4>Results</h4>By September 16, 2024 (data cutoff), 53 patients had received camizestrant plus abemaciclib, 78 camizestr","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T13:07:41.726Z","creation":"2026-05-09T03:11:34.35Z"},"accession":"S-EPMC12521909","cross_references":{"pubmed":["40788187"],"doi":["10.1158/1078-0432.CCR-25-1198"]}}